Dr. Janice Reichert, Chief Operating Officer of The Antibody Society, is an internationally-recognized expert in the development of antibody therapeutics. She is Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Dr. Silvia Crescioli is an Independant Consultant for The Antibody Society and member of The Antibody Society Communication and Membership Committee. Since 2021 she has co-authored the “Antibodies to watch” articles in published in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody therapeutics marketing application submission as well as approvals that might occur the following year. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence in 2014, followed by eight years as a post doc at King’s College London in Prof. Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she is now a visiting Research Fellow. Her research interests focus on antibody therapeutics development for both cancer and noncancer indications, as well as on different areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering and glycoengineering.
